The $77 per share offer marks an 86% premium as argenx expands its pipeline with Forte’s Phase II anti-CD122 antibody.
Argenx will acquire Forte Biosciences for $2.2bn in equity value, pending regulatory and shareholder approval. The deal, set to close in Q3 2026, includes a cash tender offer at $77 per share, an 86% premium to Forte’s recent price.
Forte’s lead asset, FB102, a first-in-class anti-CD122 antibody, targets vitiligo and celiac disease. Phase Ib data and upcoming Phase II results drove the acquisition, aligning with argenx’s immunology strategy.
Argenx CEO Karen Massey cited FB102’s clinical validation and broad potential as key factors. The deal strengthens argenx’s portfolio ahead of Phase II readouts later this year.